For the Inventor, By the Inventor

Enter assignee name

Lengnau, Switzerland

Csl Behring Lengnau Ag

USPTO Granted Patents = 13

CIPO Patents = 6

EPO Patents = 15

Trademarks = 4

Forward Citations = 6

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Sabine Pestel (8 out of 8 patents)

Thomas Weimer (8 out of 27 patents)

Stefan Schulte (6 out of 30 patents)

4. Steve Dower (4 out of 4 patents)

5. Michael Wilson (3 out of 10 patents)

6. Hans-Wilhelm Beltz (3 out of 3 patents)

7. Matthias Pelzing (3 out of 3 patents)

8. Hubert Metzner (3 out of 28 patents)

9. Dallas Hartman (3 out of 3 patents)

10. Con Panousis (2 out of 18 patents)

11. Matthew Hardy (2 out of 8 patents)

12. Arna Andrews (2 out of 2 patents)

13. Kerstin Emmrich (2 out of 2 patents)

14. Michael Moses (1 out of 3 patents)

15. Gerhard Dickneite (1 out of 29 patents)

13 patents: Sort by Forward Citations

1. 12209261 - Media for the expression of recombinant vitamin K-dependent proteins (2025-01-28),

2. 11890327 - Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder (2024-02-06),

3. 11814421 - Truncated von Willebrand Factor polypeptides for treating hemophilia (2023-11-14),

4. 11564976 - Methods for preparing modified von Willebrand Factor (2023-01-31),

5. 11479578 - Protein purification and virus inactivation with alkyl glycosides (2022-10-25),

6. 11155601 - Modified von Willebrand factor having improved half-life (2021-10-26),

7. 11141466 - Modulation of FVIII immunogenicity by truncated VWF (2021-10-12),

8. 10905747 - Methods for preparing modified von Willebrand factor (2021-02-02),

9. 10808023 - Mutated von Willebrand factor (2020-10-20),

10. 10806774 - Mutated truncated von Willebrand Factor (2020-10-20),

11. 10772936 - Methods for preparing modified von Willebrand factor (2020-09-15),

12. 10688157 - Truncated von Willebrand factor polypeptides for treating hemophilia (2020-06-23),

13. 10253088 - Modified von Willebrand Factor (2019-04-09),

CSL Behring Lengnau AG is a global biotechnology company that specializes in the research, development, and production of innovative therapies for rare and serious diseases. With a focus on the treatment of hemophilia, immune deficiencies, and other rare conditions, CSL Behring is dedicated to improving the lives of patients around the world. Their cutting-edge facilities in Lengnau, Switzerland, are equipped with state-of-the-art technology and staffed by highly skilled professionals who are committed to delivering high-quality products that meet the highest standards of safety and efficacy.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

13 Patents

#6 in Lengnau

#848 in Switzerland

#43,615 in the World

Lengnau, Switzerland

Csl Behring Lengnau Ag

Forward Citations = 6

44 inventors:

Sabine Pestel (8 out of 8 patents)

Thomas Weimer (8 out of 27 patents)

Stefan Schulte (6 out of 30 patents)

4. Steve Dower (4 out of 4 patents)

5. Michael Wilson (3 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…